Literature DB >> 12202268

Effects of ketamine on leading saccades during smooth-pursuit eye movements may implicate cerebellar dysfunction in schizophrenia.

Matthew T Avila1, Martin A Weiler, Adrienne C Lahti, Carol A Tamminga, Gunvant K Thaker.   

Abstract

OBJECTIVE: Ketamine has proved a useful probe in the study of schizophrenia. Recent studies have shown that ketamine causes abnormalities in eye tracking similar to those seen in patients with schizophrenia. The authors examined the effects of ketamine on leading saccadic eye movements, a specific component of the smooth-pursuit response shown to be abnormal in schizophrenia patients and their relatives.
METHOD: Twelve normal healthy volunteers received a 0.1 mg/kg bolus injection of ketamine or placebo in double-blind fashion during a smooth-pursuit eye-movement task. The number of leading saccades and the ratios of leading saccades to smooth-pursuit response time and to total saccadic eye-movement time were measured.
RESULTS: Ketamine significantly increased the number of leading saccades and increased the leading saccade ratios for more slowly moving targets. Similar nonsignificant effects were noted at higher target speeds. Ketamine-induced abnormalities were similar to those observed in relatives of schizophrenia patients under drug-free conditions.
CONCLUSIONS: These results suggest that neurotransmission mediated by N-methyl-D-aspartate (NMDA) is involved in eye-tracking abnormalities. The generation of disruptive leading saccades during smooth pursuit is thought to be mediated by frontal-thalamic-cerebellar circuitry. Evidence that the locus of this and other ketamine-induced smooth-pursuit eye-movement deficits involves NMDA receptor functioning in the cerebellum is suggested.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12202268     DOI: 10.1176/appi.ajp.159.9.1490

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  14 in total

Review 1.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

2.  A subanesthetic dose of ketamine in the Rhesus monkey reduces the occurrence of anticipatory saccades.

Authors:  Ilhame Ameqrane; Ameqrane Ilhame; Nicolas Wattiez; Wattiez Nicolas; Pierre Pouget; Pouget Pierre; Marcus Missal; Missal Marcus
Journal:  Psychopharmacology (Berl)       Date:  2015-07-09       Impact factor: 4.530

3.  Phencyclidine/schizophrenia: one view toward the past, the other to the future.

Authors:  Edward F Domino; Elliot D Luby
Journal:  Schizophr Bull       Date:  2012-03-05       Impact factor: 9.306

4.  NOS1AP protein levels are altered in BA46 and cerebellum of patients with schizophrenia.

Authors:  Norell M Hadzimichalis; Michelle L Previtera; Michael P Moreau; Bo Li; Gum Hwa Lee; Anna M Dulencin; Paul G Matteson; Steven Buyske; James H Millonig; Linda M Brzustowicz; Bonnie L Firestein
Journal:  Schizophr Res       Date:  2010-06-01       Impact factor: 4.939

5.  Alcohol impairment of saccadic and smooth pursuit eye movements: impact of risk factors for alcohol dependence.

Authors:  Daniel J O Roche; Andrea C King
Journal:  Psychopharmacology (Berl)       Date:  2010-07-16       Impact factor: 4.530

6.  Effects of ketamine on brain function during smooth pursuit eye movements.

Authors:  M Steffens; B Becker; C Neumann; A M Kasparbauer; I Meyhöfer; B Weber; M A Mehta; R Hurlemann; U Ettinger
Journal:  Hum Brain Mapp       Date:  2016-11       Impact factor: 5.038

Review 7.  The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia.

Authors:  Joseph T Coyle; Guochuan Tsai
Journal:  Psychopharmacology (Berl)       Date:  2003-11-25       Impact factor: 4.530

Review 8.  Neurophysiological biomarkers for drug development in schizophrenia.

Authors:  Daniel C Javitt; Kevin M Spencer; Gunvant K Thaker; Georg Winterer; Mihály Hajós
Journal:  Nat Rev Drug Discov       Date:  2008-01       Impact factor: 84.694

Review 9.  Pharmacological treatment effects on eye movement control.

Authors:  James L Reilly; Rebekka Lencer; Jeffrey R Bishop; Sarah Keedy; John A Sweeney
Journal:  Brain Cogn       Date:  2008-12       Impact factor: 2.310

10.  Is persistent ketamine use a valid model of the cognitive and oculomotor deficits in schizophrenia?

Authors:  Celia J A Morgan; Vyv Huddy; Michelle Lipton; H Valerie Curran; Eileen M Joyce
Journal:  Biol Psychiatry       Date:  2008-12-25       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.